Kelun Pharmaceutical's Subsidiary Kelun-Biotech Announces Partial Adjustment in Collaboration with MSD Regarding Preclinical ADC Assets

36Kr learned that Kelun Pharmaceutical announced its controlling subsidiary, Kelun-Biotech, received formal written notice from MSD. MSD decided to: (1) terminate the exclusive license granted by Kelun-Biotech for the development, manufacturing, and commercialization of a preclinical ADC asset; (2) not exercise the exclusive option granted by Kelun-Biotech to obtain an exclusive license for another preclinical ADC asset. The collaboration between Kelun-Biotech and MSD on three clinical-stage ADC assets and four preclinical ADC assets has not been affected.Original Link